Clinical Nuclear Medicine

Skip Navigation LinksHome > July 2013 - Volume 38 - Issue 7 > 18F-Fluorothymidine PET Is a Potential Predictive Imaging Bi...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e318292ee9c
Interesting Images

18F-Fluorothymidine PET Is a Potential Predictive Imaging Biomarker of the Response to Gemcitabine-Based Chemotherapeutic Treatment for Recurrent Ovarian Cancer: Preliminary Results in Three Patients

Tsuyoshi, Hideaki MD*; Morishita, Fumiko MD*; Orisaka, Makoto MD*; Okazawa, Hidehiko MD; Yoshida, Yoshio MD*

Collapse Box

Abstract

Abstract: In order to establish early and precise methods for evaluating the effect of secondary chemotherapy in patients with recurrent ovarian cancer, both the clinical course of 3 women treated with gemcitabine-based secondary chemotherapy and the potential for early and accurate evaluation of the secondary chemotherapeutic effect of 18F-fluorothymidine (FLT) PET are reported. Standard uptake value with FLT PET decreased earlier than with 18F-fluorodeoxyglucose PET and was better correlated with a reduction in size as measured by CT. FLT PET could become a new standard for monitoring response to gemcitabine-based secondary chemotherapy treatment for recurrent ovarian cancer.

© 2013 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.